Bleselumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD40
Clinical data
Other namesASKP1240
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6412H9906N1690O2018S38
Molar mass144175.87 g·mol−1

Bleselumab (INN;[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.[2][3]

This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.[4]

References

  1. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. ^ Wojciechowski D, Vincenti F (November 2016). "Current status of costimulatory blockade in renal transplantation". Current Opinion in Nephrology and Hypertension. 25 (6): 583–590. doi:10.1097/MNH.0000000000000268. PMID 27517137. S2CID 4379881.
  3. ^ Malvezzi P, Jouve T, Rostaing L (November 2016). "Costimulation Blockade in Kidney Transplantation: An Update". Transplantation. 100 (11): 2315–2323. doi:10.1097/TP.0000000000001344. PMC 5084636. PMID 27472094.
  4. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.
Categories